Pulmonary Arterial Hypertension (PAH) is a chronic and progressive disease of the heart and lungs that is characterized by high blood pressure inside of the blood vessels in the lungs. These blood vessels can become narrowed, blocked or destroyed, leading to right-sided heart failure if left untreated. Early symptoms are often vague (shortness of breath, fatigue), but can progress to chest pain, dizziness/lightheadedness, and passing out. It is estimated that it takes 2.8 years for a patient to be properly diagnosed with this condition and to obtain proper workup and treatment. Survival rates and quality of life is vastly improved with appropriate treatments. We are fortunate in Rhode Island to have one of the best Pulmonary Hypertension Centers in the United States at Rhode Island Hospital/University Medicine Pulmonary. Our Center provides access to all FDA-approved PAH therapies, participation in cutting-edge research studies, and a very active patient/family support group. For several years, our support group has provided a place to connect, advocate, and educate patients and their loved ones about PAH. As our support group and patient population has grown, we have witnessed the need to provide a scholarship fund for expenses that are not covered by insurance. Such expenses may include a costly electric bill from running an oxygen concentrator continuously, a co-pay for an expensive live-sustaining medication, medical equipment that is only partially covered by insurance, or assistance with travel to an out-of-state hospital for lung transplant evaluation. The burden of this disease is heavy and should not be made heavier by the uncovered costs of appropriate healthcare. We are grateful to RIBTA for support of our cause in previous years and look forward to another successful year of fundraising as a part of the Pell Run! Thank you!